Do Omega-3 Fatty Acids Have an Antidepressant Effect in Patients With Signs of Peripheral Inflammation?
NCT ID: NCT03143075
Last Updated: 2023-11-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
95 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-08-01
Study Completion Date
2023-05-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, the investigators will stratify depressed subjects a priori based on CRP levels to test the hypothesis that eicosapentaenoic (EPA) would be more efficacious to treat depression in subjects with high CRP levels compared to subjects with low CRP levels.
Depressed subjects, with ongoing stabilized antidepressive treatment who remain clinically depressed, will be enrolled in an "Inflammation group" or in a "Non-inflammation group" depending on baseline levels of CRP. Subjects in both groups will receive EPA enriched omega-3 fatty acids for 8 weeks, added to their pre-stabilized antidepressant medication.
Depressed subjects, with ongoing stabilized antidepressive treatment who remain clinically depressed, will be enrolled in an "Inflammation group" or in a "Non-inflammation group" depending on baseline levels of CRP. Subjects in both groups will receive EPA enriched omega-3 fatty acids for 8 weeks, added to their pre-stabilized antidepressant medication.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
NCT02553915
Major Depressive Disorder
Overweight
Inflammation
COMPLETED
PHASE2/PHASE3
Omega-3 Fatty Acids for Treating Adults With Major Depression
NCT00517036
Depression
COMPLETED
PHASE3
Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression
NCT00361374
Major Depressive Disorder
COMPLETED
PHASE3
A Study of Omega-3 as a Treatment for Major Depression
NCT00238758
Major Depression
Dysthymia
UNKNOWN
PHASE2
Omega-3 Polyunsaturated Fatty Acids on Major Depressive Disorder in Patients With Cardiovascular Diseases
NCT03072823
Cardiovascular Diseases
Major Depressive Disorder
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background
Increased mean levels of peripheral inflammatory markers have repeatedly been reported in individuals with major depression compared to controls, although there is considerable overlap between groups. As further evidence for a role of inflammation in major depression, 20-60% of patients receiving treatment for viral hepatitis and certain forms of cancer with the cytokine interferon-alpha will develop depressive symptoms. Interestingly, some authors have suggested that the association between inflammation and depression is symptom specific, i.e. there might be a subtype of "inflammation-related depression" with a specific phenotype. Although it still remains unclear if the immune abnormalities often seen in depressed subjects derive from changes in the periphery or in the central nervous system (or both), animal studies have shown that by counteracting the effects of pro-inflammatory cytokines in either the blood or the brain, depressive-like behavior in animals can be mitigated. These animal studies, along with data from several clinical studies pertaining to this, suggest that interventions primarily targeting peripheral inflammation may be useful in treating psychiatric symptoms. Although the exact mechanisms by which increased inflammation may give rise to depressive symptoms remain unclear, there are several potential downstream pathways that may be involved including accelerated cellular aging, mitochondrial dysfunction, and oxidative stress.
In search for a potential antidepressant that could be tested in clinical trials in which subjects are selected a priori based on inflammatory markers, the investigators turn to eicosapentaenoic (EPA), an omega-3 (n-3) fatty acid with anti-inflammatory properties. The ability of dietary n-3 fatty acids to mitigate the inflammatory response has been shown in human and animal studies. EPA and Docosahexaenoic acid (DHA) are the two major n-3 fatty acids found in oily fish and fish oil supplements, and both have shown anti-inflammatory properties. Supplementation of EPA and DHA in individuals with cardiovascular disease results in decreased plasma levels of CRP. N-3 fatty acids also have several other anti-inflammatory properties including i) Decreased chemotaxis of neutrophils and monocytes, ii) Decreased expression of adhesion molecules (e.g. ICAM \& VCAM) on the surface of immune cells and in the circulation, iii) Decreased production of prostaglandins, iv) Increased synthesis of anti-inflammatory molecules such as resolvins and protectins, and v) Inhibition of T-cell proliferation. The mechanisms underlying these effects are not fully understood but likely involves n-3 fatty acids acting via cell surface and intracellular receptors controlling inflammatory cell signaling and gene expression patterns. In addition to the well-established anti-inflammatory effects of n-3 fatty acids, they may also have beneficial effects on oxidative stress and cell aging parameters such as leukocyte telomere length and telomerase activity. However, more research is needed in order to confirm these relationships, and therefore the investigators will, in addition to assessing inflammatory markers, also study the effects of n-3 fatty acids on markers of cellular aging and oxidative stress.
Some, but not all, previous studies have shown that EPA is superior to placebo in treating unipolar or bipolar depression. Several caveats have, however, been issued when interpreting the results from these studies, including small and perhaps clinically irrelevant effect sizes, as well as potential publication bias. Generally, n-3 preparations with high doses of EPA relative to DHA have been shown to be more efficacious in treating depression. Interestingly, a double blind placebo-controlled RCT showed that that EPA (but not DHA) was effective in preventing interferon-alpha induced depression in hepatitis C subjects, consistent with the notion that EPA may have antidepressant effect in "inflammatory depression". In line with this notion, a recent a proof-of-concept study showed that high inflammation at baseline was associated with a better antidepressant effect of EPA, but not DHA, enriched n-3 compared to placebo. That study stratified subjects post-hoc based on inflammatory markers, whereas our approach will be to select study subjects a priori based on validated cut-offs for CRP. This is the next step in developing a personalized medicine paradigm for depression.
The main aims of the study are to test if i) EPA enriched n-3 (added to stabilized ongoing treatment) is efficacious in treating depressed patients, but only in subjects with prospectively ascertained elevations in baseline CRP, ii) Changes in inflammatory markers over the course of treatment mediate this effect, and iii) Clinical trial designs utilizing prospectively-ascertained biomarkers to predict response are feasible and thereby pave the way for personalized medicine in psychiatry.
Specific objective 1: To determine whether the antidepressant effect of n-3 EPA is greater in the Inflammation group than in the Non-inflammation group, controlling for baseline depression rating.
Hypothesis (H) 1: The antidepressant effect of n-3 EPA is greater in the Inflammation group than in the Non-inflammation group.
Specific objective 2: To determine whether changes in inflammatory, oxidative stress and cell aging markers from baseline to end of treatment correlate with antidepressant effect.
H 2: Change in inflammatory and cell aging markers with n-3 EPA treatment will be directly correlated with changes in depression ratings.
Increased mean levels of peripheral inflammatory markers have repeatedly been reported in individuals with major depression compared to controls, although there is considerable overlap between groups. As further evidence for a role of inflammation in major depression, 20-60% of patients receiving treatment for viral hepatitis and certain forms of cancer with the cytokine interferon-alpha will develop depressive symptoms. Interestingly, some authors have suggested that the association between inflammation and depression is symptom specific, i.e. there might be a subtype of "inflammation-related depression" with a specific phenotype. Although it still remains unclear if the immune abnormalities often seen in depressed subjects derive from changes in the periphery or in the central nervous system (or both), animal studies have shown that by counteracting the effects of pro-inflammatory cytokines in either the blood or the brain, depressive-like behavior in animals can be mitigated. These animal studies, along with data from several clinical studies pertaining to this, suggest that interventions primarily targeting peripheral inflammation may be useful in treating psychiatric symptoms. Although the exact mechanisms by which increased inflammation may give rise to depressive symptoms remain unclear, there are several potential downstream pathways that may be involved including accelerated cellular aging, mitochondrial dysfunction, and oxidative stress.
In search for a potential antidepressant that could be tested in clinical trials in which subjects are selected a priori based on inflammatory markers, the investigators turn to eicosapentaenoic (EPA), an omega-3 (n-3) fatty acid with anti-inflammatory properties. The ability of dietary n-3 fatty acids to mitigate the inflammatory response has been shown in human and animal studies. EPA and Docosahexaenoic acid (DHA) are the two major n-3 fatty acids found in oily fish and fish oil supplements, and both have shown anti-inflammatory properties. Supplementation of EPA and DHA in individuals with cardiovascular disease results in decreased plasma levels of CRP. N-3 fatty acids also have several other anti-inflammatory properties including i) Decreased chemotaxis of neutrophils and monocytes, ii) Decreased expression of adhesion molecules (e.g. ICAM \& VCAM) on the surface of immune cells and in the circulation, iii) Decreased production of prostaglandins, iv) Increased synthesis of anti-inflammatory molecules such as resolvins and protectins, and v) Inhibition of T-cell proliferation. The mechanisms underlying these effects are not fully understood but likely involves n-3 fatty acids acting via cell surface and intracellular receptors controlling inflammatory cell signaling and gene expression patterns. In addition to the well-established anti-inflammatory effects of n-3 fatty acids, they may also have beneficial effects on oxidative stress and cell aging parameters such as leukocyte telomere length and telomerase activity. However, more research is needed in order to confirm these relationships, and therefore the investigators will, in addition to assessing inflammatory markers, also study the effects of n-3 fatty acids on markers of cellular aging and oxidative stress.
Some, but not all, previous studies have shown that EPA is superior to placebo in treating unipolar or bipolar depression. Several caveats have, however, been issued when interpreting the results from these studies, including small and perhaps clinically irrelevant effect sizes, as well as potential publication bias. Generally, n-3 preparations with high doses of EPA relative to DHA have been shown to be more efficacious in treating depression. Interestingly, a double blind placebo-controlled RCT showed that that EPA (but not DHA) was effective in preventing interferon-alpha induced depression in hepatitis C subjects, consistent with the notion that EPA may have antidepressant effect in "inflammatory depression". In line with this notion, a recent a proof-of-concept study showed that high inflammation at baseline was associated with a better antidepressant effect of EPA, but not DHA, enriched n-3 compared to placebo. That study stratified subjects post-hoc based on inflammatory markers, whereas our approach will be to select study subjects a priori based on validated cut-offs for CRP. This is the next step in developing a personalized medicine paradigm for depression.
The main aims of the study are to test if i) EPA enriched n-3 (added to stabilized ongoing treatment) is efficacious in treating depressed patients, but only in subjects with prospectively ascertained elevations in baseline CRP, ii) Changes in inflammatory markers over the course of treatment mediate this effect, and iii) Clinical trial designs utilizing prospectively-ascertained biomarkers to predict response are feasible and thereby pave the way for personalized medicine in psychiatry.
Specific objective 1: To determine whether the antidepressant effect of n-3 EPA is greater in the Inflammation group than in the Non-inflammation group, controlling for baseline depression rating.
Hypothesis (H) 1: The antidepressant effect of n-3 EPA is greater in the Inflammation group than in the Non-inflammation group.
Specific objective 2: To determine whether changes in inflammatory, oxidative stress and cell aging markers from baseline to end of treatment correlate with antidepressant effect.
H 2: Change in inflammatory and cell aging markers with n-3 EPA treatment will be directly correlated with changes in depression ratings.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Major Depressive Disorder
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
Match/mismatch design (based on CRP levels), all subjects receive the same dose of EPA, no one receives placebo. Raters are blind to "Inflammation group" or "Non-inflammation group" allocation
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Investigators
Outcome Assessors
Raters are blind to "Inflammation group" or "Non-inflammation group" allocation
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Inflammation group
Subjects with CRP≥3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
Group Type
ACTIVE_COMPARATOR
Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day
Intervention Type
DIETARY_SUPPLEMENT
Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
Non-inflammation group
Subjects with CRP\<3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
Group Type
ACTIVE_COMPARATOR
Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day
Intervention Type
DIETARY_SUPPLEMENT
Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day
Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male/female, aged 18-80.
2. Fulfilling the DSM criteria for a current depressive episode, unipolar (symptom duration\> 4 weeks) as determined by the study physician
3. HAM-D-17 score ≥ 15 (Rapaport, Nierenberg et al. 2016)
4. A Clinical Global Impression Severity Score ≥ 3 (Rapaport, Nierenberg et al. 2016)
5. All subjects should be stable on antidepressants or mood stabilizers ≥6 weeks.
6. Willing to not significantly modify their diet from the time they sign consent through the end of study participation.
2. Fulfilling the DSM criteria for a current depressive episode, unipolar (symptom duration\> 4 weeks) as determined by the study physician
3. HAM-D-17 score ≥ 15 (Rapaport, Nierenberg et al. 2016)
4. A Clinical Global Impression Severity Score ≥ 3 (Rapaport, Nierenberg et al. 2016)
5. All subjects should be stable on antidepressants or mood stabilizers ≥6 weeks.
6. Willing to not significantly modify their diet from the time they sign consent through the end of study participation.
Exclusion Criteria
1. Serious or unstable medical illness that in the investigator's opinion could compromise response to treatment or interpretation of study results. Examples: Malignancy not in remission for at least 1 year, Active autoimmune disorder or inflammatory bowel disease, Insulin-dependent diabetes mellitus.
2. Known or suspected allergy to the study compounds.
3. Ongoing infection.
4. Ongoing pregnancy or breast-feeding
5. A diagnosis of psychotic disorder, bipolar disorder, mental retardation dementia, or individual whom, due to other causes, lack the ability to make an informed decision.
6. Ongoing ECT.
7. Concomitant use of anticoagulants or known bleeding disorder.
8. Patients who, in the investigator's judgment, pose a current, serious suicidal or homicidal risk.
9. A diagnosis for any Substance Use Disorder (except nicotine or caffeine) in the 3 months prior to the screening visit.
10. Any medications (within 1 week of baseline or during the trial) that might confound the biomarker findings, including: Regular ingestion of NSAIDs or COX-2 inhibitors, or any use of oral steroids, immunosuppressants, interferon, chemotherapy (Patients will be instructed not to take an NSAID, COX-2 inhibitor or Aspirin in the 24 hours prior to a biomarker assessment visit).
11. Patients who have taken supplements with omega-3 fatty acids for more than three consecutive days in the preceding month.
12. Within 4 weeks of starting psychotherapy or planning to start psychotherapy during the study
13. Active participation in other clinical studies with ongoing study visits
\-
2. Known or suspected allergy to the study compounds.
3. Ongoing infection.
4. Ongoing pregnancy or breast-feeding
5. A diagnosis of psychotic disorder, bipolar disorder, mental retardation dementia, or individual whom, due to other causes, lack the ability to make an informed decision.
6. Ongoing ECT.
7. Concomitant use of anticoagulants or known bleeding disorder.
8. Patients who, in the investigator's judgment, pose a current, serious suicidal or homicidal risk.
9. A diagnosis for any Substance Use Disorder (except nicotine or caffeine) in the 3 months prior to the screening visit.
10. Any medications (within 1 week of baseline or during the trial) that might confound the biomarker findings, including: Regular ingestion of NSAIDs or COX-2 inhibitors, or any use of oral steroids, immunosuppressants, interferon, chemotherapy (Patients will be instructed not to take an NSAID, COX-2 inhibitor or Aspirin in the 24 hours prior to a biomarker assessment visit).
11. Patients who have taken supplements with omega-3 fatty acids for more than three consecutive days in the preceding month.
12. Within 4 weeks of starting psychotherapy or planning to start psychotherapy during the study
13. Active participation in other clinical studies with ongoing study visits
\-
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Francisco
OTHER
Sponsor Role
collaborator
Region Skane
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lund University, Dept of Psychiatry
Lund, , Sweden
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Sweden
References
Explore related publications, articles, or registry entries linked to this study.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010 Mar 1;67(5):446-57. doi: 10.1016/j.biopsych.2009.09.033. Epub 2009 Dec 16.
Reference Type
BACKGROUND
Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19(2):105-23. doi: 10.2165/00023210-200519020-00002.
Reference Type
BACKGROUND
Jokela M, Virtanen M, Batty GD, Kivimaki M. Inflammation and Specific Symptoms of Depression. JAMA Psychiatry. 2016 Jan;73(1):87-8. doi: 10.1001/jamapsychiatry.2015.1977. No abstract available.
Reference Type
BACKGROUND
Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep. 2011 Dec;13(6):467-75. doi: 10.1007/s11920-011-0232-0.
Reference Type
BACKGROUND
Miller AH, Haroon E, Felger JC. Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation. Neuropsychopharmacology. 2017 Jan;42(1):334-359. doi: 10.1038/npp.2016.167. Epub 2016 Aug 24.
Reference Type
BACKGROUND
Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry. 2016 Jan;21(1):71-9. doi: 10.1038/mp.2015.22. Epub 2015 Mar 24.
Reference Type
BACKGROUND
Lindqvist D, Epel ES, Mellon SH, Penninx BW, Revesz D, Verhoeven JE, Reus VI, Lin J, Mahan L, Hough CM, Rosser R, Bersani FS, Blackburn EH, Wolkowitz OM. Psychiatric disorders and leukocyte telomere length: Underlying mechanisms linking mental illness with cellular aging. Neurosci Biobehav Rev. 2015 Aug;55:333-64. doi: 10.1016/j.neubiorev.2015.05.007. Epub 2015 May 18.
Reference Type
BACKGROUND
Babcock T, Helton WS, Espat NJ. Eicosapentaenoic acid (EPA): an antiinflammatory omega-3 fat with potential clinical applications. Nutrition. 2000 Nov-Dec;16(11-12):1116-8. doi: 10.1016/s0899-9007(00)00392-0. No abstract available.
Reference Type
BACKGROUND
Rangel-Huerta OD, Aguilera CM, Mesa MD, Gil A. Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomakers: a systematic review of randomised clinical trials. Br J Nutr. 2012 Jun;107 Suppl 2:S159-70. doi: 10.1017/S0007114512001559.
Reference Type
BACKGROUND
Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2013 Mar;75(3):645-62. doi: 10.1111/j.1365-2125.2012.04374.x.
Reference Type
BACKGROUND
Kiecolt-Glaser JK, Epel ES, Belury MA, Andridge R, Lin J, Glaser R, Malarkey WB, Hwang BS, Blackburn E. Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial. Brain Behav Immun. 2013 Feb;28:16-24. doi: 10.1016/j.bbi.2012.09.004. Epub 2012 Sep 23.
Reference Type
BACKGROUND
Saunders EF, Ramsden CE, Sherazy MS, Gelenberg AJ, Davis JM, Rapoport SI. Omega-3 and Omega-6 Polyunsaturated Fatty Acids in Bipolar Disorder: A Review of Biomarker and Treatment Studies. J Clin Psychiatry. 2016 Oct;77(10):e1301-e1308. doi: 10.4088/JCP.15r09925.
Reference Type
BACKGROUND
Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry. 2012 Dec;17(12):1272-82. doi: 10.1038/mp.2011.100. Epub 2011 Sep 20.
Reference Type
BACKGROUND
Mocking RJ, Harmsen I, Assies J, Koeter MW, Ruhe HG, Schene AH. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry. 2016 Mar 15;6(3):e756. doi: 10.1038/tp.2016.29.
Reference Type
BACKGROUND
Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003 Aug;13(4):267-71. doi: 10.1016/s0924-977x(03)00032-4.
Reference Type
BACKGROUND
Hieronymus F, Emilsson JF, Nilsson S, Eriksson E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry. 2016 Apr;21(4):523-30. doi: 10.1038/mp.2015.53. Epub 2015 Apr 28.
Reference Type
BACKGROUND
Suneson K, Soderberg Veiback G, Lindahl J, Tjernberg J, Stahl D, Ventorp S, Angeby F, Lundblad K, Wolkowitz OM, Lindqvist D. Omega-3 fatty acids for inflamed depression - A match/mismatch study. Brain Behav Immun. 2024 May;118:192-201. doi: 10.1016/j.bbi.2024.02.029. Epub 2024 Mar 1.
Reference Type
DERIVED
Suneson K, Angeby F, Lindahl J, Soderberg G, Tjernberg J, Lindqvist D. Efficacy of eicosapentaenoic acid in inflammatory depression: study protocol for a match-mismatch trial. BMC Psychiatry. 2022 Dec 19;22(1):801. doi: 10.1186/s12888-022-04430-z.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017150
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression
NCT00289484
UNKNOWN
PHASE2
N-3 Fatty Acids as the First-line Antidepressant Therapy: From Biomarkers to Clinical Subtypes
NCT03871088
COMPLETED
NA
Fish Oil as Adjunct Treatment for Major Depressive Disorder
NCT03295708
UNKNOWN
NA
PUFA Augmentation in Treatment of Major Depression
NCT00067301
COMPLETED
PHASE3
Omega 3 for Treatment of Depression in Patients With Heart Failure
NCT02057406
COMPLETED
PHASE3
Study of Supplementation of Antidepressants With Fish Oil to Improve Time to Clinical Response
NCT00963196
WITHDRAWN
NA
The Effect of Fish Oil in Major Depressive Disorder
NCT00816322
COMPLETED
NA
Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
NCT00511810
COMPLETED
PHASE2/PHASE3
Omega-3 Fatty Acids in Adolescent Depression
NCT00312897
COMPLETED
PHASE2
Cytokines, PUFA Tissue Concentrations and Treatment Selection in Antenatal MDD
NCT03101540
TERMINATED
EARLY_PHASE1
Role of Omega-3 Polyunsaturated Fatty Acid in the Management of Major Depressive Disorder.
NCT03732378
COMPLETED
NA
Omega-3 for Depression and Other Cardiac Risk Factors - 2
NCT02021669
COMPLETED
PHASE2
N-3 Polyunsaturated Fatty Acids in the Prevention and Treatment for IFN-induced Depression
NCT01620502
COMPLETED
NA
A Prophylactic Trial of Omega-3 Polyunsaturated Fatty Acids in Bipolar Disorder
NCT04210804
COMPLETED
PHASE2
Omega-3 Unsaturated Fatty Acid Improves Cognitive Function in Patients With Depression
NCT04803071
UNKNOWN
NA
Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During Pregnancy
NCT03101527
TERMINATED
EARLY_PHASE1
The Efficacy of Omega-3 Fatty Acids in Maintaining Optimal Mental Health in Elderly People
NCT00124852
COMPLETED
NA
Use of Omega-3 Fatty Acids for Perinatal Depression
NCT00402389
COMPLETED
PHASE2
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
NCT01803711
TERMINATED
PHASE2/PHASE3
The Omega-3 Fatty Acid Paediatric Depression Trial
NCT03167307
COMPLETED
PHASE3
A Clinical Study of Omega-3 on Depression and Cognition
NCT05941754
UNKNOWN
NA
Omega-3 Fatty Acids for Treatment of Depression in Adolescents
NCT00658476
COMPLETED
PHASE3
Does Fish Oil Prevent Depression in Pregnancy and Postpartum?
NCT00711971
COMPLETED
PHASE2/PHASE3
Omega-3 for Peri- and Postmenopausal Depression
NCT00825994
COMPLETED
NA
Essential Fatty Acids for Major Depression
NCT00256412
COMPLETED
NA